Trial Profile

A Phase 3 Study multi-center, randomized, double-blind, safety and efficacy trial of mdc-CWM for Post-Operative Pain and Inflammation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Sep 2024 According to MedinCell media release, the company plans to meet with FDA in Q4 2024 to discuss additional studies required for approval.
03 Sep 2024 Status changed from active, no longer recruiting to completed., as per Medincell media release.
14 May 2024 Primary endpoint (time-weighted AUC of pain intensity over 14 days when comparing treatment with multimodal analgesia (MMA) alone to MMA concurrent with a single dose of F14 administered in the knee at the time of Total Knee Replacement (TKR).) has not been met as per MedinCell Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com